Literature DB >> 2460273

Induction of antigen-specific suppression by circulating Cryptococcus neoformans antigen.

J W Murphy1, R A Cox.   

Abstract

Immunoaffinity chromatography of sera from mice infected with Cryptococcus neoformans (Inf-MS) on a column with rabbit anti-cryptococcal antibody as the ligand resulted in the adsorption of the component(s) that induce suppression of the cryptococcal delayed-type hypersensitivity (DTH) response. In contrast, immunoaffinity chromatography of Inf-MS on columns coupled with cryptococcal antigen or goat anti-mouse IgM, IgG, and IgA did not adsorb the suppressive component(s). Quantification of cryptococcal antigen and anti-cryptococcal antibody in Inf-MS and column fractions established a direct correlation between cryptococcal antigen levels and suppressive activity; no correlation was observed between anti-cryptococcal antibody levels and suppressive activity. The suppression induced by Inf-MS was shown to be specific in that suppressive sera did not affect the induction of DTH responses to Listeria monocytogenes or dinitrofluorobenzene. These collective results provide evidence that cryptococcal antigen is the component in Inf-MS that induces antigen-specific suppression of the cell-mediated immune response to C. neoformans.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2460273      PMCID: PMC1541611     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  27 in total

1.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

Review 2.  Suppressor cells and immunoregulation.

Authors:  M E Dorf; B Benacerraf
Journal:  Annu Rev Immunol       Date:  1984       Impact factor: 28.527

Review 3.  An overview of T-suppressor cell circuits.

Authors:  G L Asherson; V Colizzi; M Zembala
Journal:  Annu Rev Immunol       Date:  1986       Impact factor: 28.527

4.  In vitro human lymphocyte responses to Cryptococcus neoformans. Evidence for primary and secondary responses in normals and infected subjects.

Authors:  G P Miller; J Puck
Journal:  J Immunol       Date:  1984-07       Impact factor: 5.422

5.  Regulation of cell-mediated immunity in cryptococcosis. I. Induction of specific afferent T suppressor cells by cryptococcal antigen.

Authors:  J W Murphy; J W Moorhead
Journal:  J Immunol       Date:  1982-01       Impact factor: 5.422

6.  Immunoadsorption of Cryptococcus-specific suppressor T-cell factors.

Authors:  R L Mosley; J W Murphy; R A Cox
Journal:  Infect Immun       Date:  1986-03       Impact factor: 3.441

7.  Regulation of cell-mediated immunity in cryptococcosis. II. Characterization of first-order T suppressor cells (Ts1) and induction of second-order suppressor cells.

Authors:  J W Murphy; R L Mosley; J W Moorhead
Journal:  J Immunol       Date:  1983-06       Impact factor: 5.422

8.  Regulation of cell-mediated immunity in cryptococcosis. III. Characterization of second-order T suppressor cells (Ts2).

Authors:  J W Murphy; R L Mosley
Journal:  J Immunol       Date:  1985-01       Impact factor: 5.422

9.  Effects of first-order Cryptococcus-specific T-suppressor cells on induction of cells responsible for delayed-type hypersensitivity.

Authors:  J W Murphy
Journal:  Infect Immun       Date:  1985-05       Impact factor: 3.441

10.  Analysis of T cell hybridomas. II. Comparisons among three distinct types of monoclonal suppressor factors.

Authors:  K Okuda; M Minami; M Furusawa; M E Dorf
Journal:  J Exp Med       Date:  1981-12-01       Impact factor: 14.307

View more
  10 in total

1.  Pathogenesis of Cryptococcus neoformans in congenitally immunodeficient beige athymic mice.

Authors:  C A Salkowski; E Balish
Journal:  Infect Immun       Date:  1990-10       Impact factor: 3.441

2.  Encapsulation of Cryptococcus neoformans with glucuronoxylomannan inhibits the antigen-presenting capacity of monocytes.

Authors:  C Retini; A Vecchiarelli; C Monari; F Bistoni; T R Kozel
Journal:  Infect Immun       Date:  1998-02       Impact factor: 3.441

3.  Tissue localization of Cryptococcus neoformans glucuronoxylomannan in the presence and absence of specific antibody.

Authors:  D L Goldman; S C Lee; A Casadevall
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

4.  Phenotypic switching in the human pathogenic fungus Cryptococcus neoformans is associated with changes in virulence and pulmonary inflammatory response in rodents.

Authors:  D L Goldman; B C Fries; S P Franzot; L Montella; A Casadevall
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-08       Impact factor: 11.205

5.  Delayed-type hypersensitivity response in an isogenic murine model of paracoccidioidomycosis.

Authors:  R dos A Fazioli; L M Singer-Vermes; S S Kashino; E Burger; M F De Franco; M Moscardi-Bacchi; V L Calich
Journal:  Mycopathologia       Date:  1994-06       Impact factor: 2.574

6.  Clearance of Cryptococcus neoformans from immunologically suppressed mice.

Authors:  J W Murphy
Journal:  Infect Immun       Date:  1989-07       Impact factor: 3.441

7.  Regulation of cytokine production during the expression phase of the anticryptococcal delayed-type hypersensitivity response.

Authors:  K L Buchanan; J W Murphy
Journal:  Infect Immun       Date:  1994-07       Impact factor: 3.441

8.  Characterization of cellular infiltrates and cytokine production during the expression phase of the anticryptococcal delayed-type hypersensitivity response.

Authors:  K L Buchanan; J W Murphy
Journal:  Infect Immun       Date:  1993-07       Impact factor: 3.441

Review 9.  What makes Cryptococcus neoformans a pathogen?

Authors:  K L Buchanan; J W Murphy
Journal:  Emerg Infect Dis       Date:  1998 Jan-Mar       Impact factor: 6.883

10.  The mouse antibody response to infection with Cryptococcus neoformans: VH and VL usage in polysaccharide binding antibodies.

Authors:  A Casadevall; M D Scharff
Journal:  J Exp Med       Date:  1991-07-01       Impact factor: 14.307

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.